Agile Therapeutics, Inc. (AGRX)
OTCMKTS: AGRX · Delayed Price · USD
1.410
-0.010 (-0.70%)
Jul 2, 2024, 3:55 PM EDT - Market closed
Agile Therapeutics Revenue
Agile Therapeutics had revenue of $21.50M in the twelve months ending March 31, 2024, with 66.15% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $5.72M with 49.91% year-over-year growth. In the year 2023, Agile Therapeutics had annual revenue of $19.59M with 80.02% growth.
Revenue (ttm)
$21.50M
Revenue Growth
+66.15%
P/S Ratio
0.45
Revenue / Employee
$1,131,316
Employees
19
Market Cap
9.67M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 19.59M | 8.71M | 80.02% |
Dec 31, 2022 | 10.88M | 6.78M | 165.40% |
Dec 31, 2021 | 4.10M | 3.35M | 447.53% |
Dec 31, 2020 | 749.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
AGRX News
- 4 days ago - AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX - Business Wire
- 6 days ago - AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders - Business Wire
- 6 days ago - Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. - GlobeNewsWire
- 6 weeks ago - Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Agile Therapeutics Announces Delisting from Nasdaq - GlobeNewsWire
- 3 months ago - Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 - GlobeNewsWire
- 3 months ago - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 - GlobeNewsWire